News
QLGN
0.3200
+8.36%
0.0247
Weekly Report: what happened at QLGN last week (0415-0419)?
Weekly Report · 1d ago
MARIZYME INC - QUALIGEN WILL HELP SUPPORT COMMERCIAL LAUNCH IN UNITED STATES OF DURAGRAFT
Reuters · 04/16 11:00
MARIZYME ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH QUALIGEN THERAPEUTICS FOR THE COMMERCIALIZATION OF FDA-CLEARED DURAGRAFT™
Reuters · 04/16 11:00
MARIZYME INC - QUALIGEN PURCHASED EXCLUSIVE NEGOTIATION PERIOD ENDING MAY 31 FOR PROPOSING BROADER STRATEGIC RELATIONSHIP BETWEEN TWO COMPANIES
Reuters · 04/16 11:00
Weekly Report: what happened at QLGN last week (0408-0412)?
Weekly Report · 04/15 12:06
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented At American Association Of Cancer Research 2024 Annual Meeting
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors presented at the American Association for Cancer Research Annual Meeting 2024 in San Diego, California. Qualigen Therapeutics has developed a series of compounds to target and disrupt the activity and signaling of various RAS mutations. The compounds can interfere with both mutant and wild type RAS.
Benzinga · 04/10 12:06
QUALIGEN THERAPEUTICS ANNOUNCES POSTER FEATURING POSITIVE EARLY CLINICAL EXPERIENCE WITH QN-302, A NOVEL FIRST-IN-CLASS G-QUADRUPLEX EXPERIMENTAL ANTI-CANCER DRUG, AT THE AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) 2024 ANNUAL MEETING
Reuters · 04/09 12:00
Weekly Report: what happened at QLGN last week (0401-0405)?
Weekly Report · 04/08 12:13
Financial Report: QLGN - NanoSynex Ltd and Subsidiaries
Press release · 04/08 10:31
Weekly Report: what happened at QLGN last week (0325-0329)?
Weekly Report · 04/01 12:09
Qualigen Therapeutics Ends Deal with Pan-RAS Holdings
TipRanks · 03/28 20:25
Weekly Report: what happened at QLGN last week (0318-0322)?
Weekly Report · 03/25 12:13
Weekly Report: what happened at QLGN last week (0311-0315)?
Weekly Report · 03/18 12:11
Weekly Report: what happened at QLGN last week (0304-0308)?
Weekly Report · 03/11 12:06
Weekly Report: what happened at QLGN last week (0226-0301)?
Weekly Report · 03/04 12:09
12 Health Care Stocks Moving In Tuesday's Intraday Session
Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutic shares moved upwards by 91.96% as the company's Q4 earnings report came out.
Benzinga · 02/27 17:31
Qualigen Therapeutics Secures Investment and Expands Financing Options
TipRanks · 02/27 12:12
Weekly Report: what happened at QLGN last week (0219-0223)?
Weekly Report · 02/26 12:29
Qualigen Therapeutics Inks Exclusive RAS Program Deal
TipRanks · 02/22 21:25
Weekly Report: what happened at QLGN last week (0212-0216)?
Weekly Report · 02/19 12:32
More
Webull provides a variety of real-time QLGN stock news. You can receive the latest news about Qualigen Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About QLGN
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.